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Editorial 
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Beyond their major ecolophysiological functions, phytoplankton pigments exert biological 
and pharmacological activities in human cells that allows to consider their clinical use to 
cure various pathologies. Although much of our knowledge relating to their cell 
pharmacology and bioactivity has come from in vitro studies in cell culture models, recent in 
vivo studies have validated the potential of phytoplankton carotenoid pigments to limit 
inflammation and metabolic disorders, retinal diseases, degenerative diseases, tumor 
progression, and hepatotoxicity. Aside from these promising results, additional studies are 
now required to precise their pharmacokinetics, pharmacological targets, and clinical 
efficacy in humans. The availability of highly purified pigments at rational costs will be a 
milestone to set up clinical trials and develop new therapies using microalgae pigments. This 
short paper focuses on the great potential of phytoplankton carotenoid pigments to prevent 
and cure cancers. 
 
Marine and freshwater microalgae have evolved a wide range of pigments that belong to the 
chlorophylls, carotenoids and phycobiliproteins families. Extensive research has proved that 
microalgae pigments exert significant biological and pharmacological activities in human 
cells. Beyond their well-known antioxidant activity, used as a commercial argument to sell 
algae-based cosmetics and nutraceutics, it is now clearly established that microalgae pigments 
have a great potential as health nutrients to prevent cancer, as biotechnological probes for 
cancer diagnosis and as anticancer drugs to trigger cancer cells apoptosis, prevent tumor 
angiogenesis, reduce the risk of metastasis, sensitize cancer cells to chemotherapy, destroy 
cancer cells by tumor phototherapy and filter UV to limit cancer cells initiation. Numerous 
studies aiming to identify antiproliferative molecules from microalgae extracts led to the 
isolation of carotenoids and to the demonstration of their high antiproliferative, cytostatic, 
cytotoxic, and/or pro-apoptotic activity in cancer cell cultures. As an example, our research 
team performed the bioguided isolation of pigments from Duniella tertiolecta and found that 
violaxanthin was the most antiproliferative molecule contained in Dt dichloromethane extract. 
We also recently reported the strong antiproliferative activity of zeaxanthin and -
cryptoxanthin in human invasive melanoma cells, after their bioguided isolation from 
Cyanophora paradoxa ethanolic extracts.  
Besides the purification of antiproliferative pigments, additional studies established that 
multiple cellular and molecular processes are affected by microalgae carotenoids. It was first 
demonstrated that their antioxidant activity protects against ROS-induced DNA mutations, 
and tissue and animals studies confirmed that most carotenoids effectively reduce the 
inflammatory processes initiated by carcinogenic agents, and thus prevent the risk of cancer 
initiation. As an example, adding peridinin in the dietary water of mice limits the 
development of carcinogens-induced skin tumors. Some authors also demonstrated that in 
addition to the cancer preventive effect associated to their antioxidant activity, some 
carotenoids such as fucoxanthin could trigger apoptosis in cancer cells by ROS generation. 
Pharmacological studies performed with fucoxanthin and various epoxycarotenoids confirmed 
that they affect a multitude of molecular and cellular targets dysregulated in cancer cells 
(cyclin-dependent kinases, DNA polymerases, connexins, pro and antiapoptotic proteins, 
MAP kinases, NF-kB, …), and numerous studies are currently undertaken to precise the 
pharmacology of carotenoids, according to their high interest for human oncology. Beyond 
their cytotoxic activity, some carotenoids also inhibit the tumor neovascularization and the 
metastatic potential of cancer cells, reverse multi-drug resistance in cancer cells treated with 
chemotherapeutic agents, and alleviate the deleterious side effects of cytotoxic drugs. 
Fucoxanthin was particularly well studied and its clinical efficacy to cure cancers from 
various tissular origin is validated in animal models, and should soon be validated in humans.  
As a conclusion, it is obvious that microalgae carotenoids have a key role to play in clinical 
oncology and cancer nutritional prevention, according to their remarkable pharmacological 
activities. In addition to synthesizing most of the oxygen that we breathe, microalgae could 
thus have a great potential to help us fighting the second cause of death in developed 
countries. 
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